SVRA Quote, Financials, Valuation and Earnings

Applied Therapeutics, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of -1899%. Savara, Inc.'s return on equity of -78.83% beat Applied Therapeutics, Inc.'s return on equity of -77.88%.

Savara, Inc. has a consensus price target of $10.31, signalling upside risk potential of 58.65%. On the other hand Applied Therapeutics, Inc. has an analysts' consensus of $1.33 which suggests that it could grow by 515.57%. Given that Applied Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Applied Therapeutics, Inc. is more attractive than Savara, Inc..

Savara, Inc. has a beta of 0.226, which suggesting that the stock is 77.376% less volatile than S&P 500. In comparison Applied Therapeutics, Inc. has a beta of 1.989, suggesting its more volatile than the S&P 500 by 98.936%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Applied Therapeutics, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than Applied Therapeutics, Inc. quarterly revenues of $1M. Savara, Inc.'s net income of -$29.6M is lower than Applied Therapeutics, Inc.'s net income of -$19M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Applied Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 30.84x for Applied Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of -255.85%. Savara, Inc.'s return on equity of -78.83% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Savara, Inc. has a consensus price target of $10.31, signalling upside risk potential of 58.65%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Savara, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Savara, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Savara, Inc. has a beta of 0.226, which suggesting that the stock is 77.376% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Savara, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Savara, Inc.'s net income of -$29.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Savara, Inc.'s net margin of --. Savara, Inc.'s return on equity of -78.83% beat Palatin Technologies's return on equity of --.

Savara, Inc. has a consensus price target of $10.31, signalling upside risk potential of 58.65%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Savara, Inc., analysts believe Palatin Technologies is more attractive than Savara, Inc..

Savara, Inc. has a beta of 0.226, which suggesting that the stock is 77.376% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Savara, Inc.'s net income of -$29.6M is higher than Palatin Technologies's net income of --. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sensus Healthcare, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of -13.7%. Savara, Inc.'s return on equity of -78.83% beat Sensus Healthcare, Inc.'s return on equity of -5.65%.

Savara, Inc. has a consensus price target of $10.31, signalling upside risk potential of 58.65%. On the other hand Sensus Healthcare, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 88.03%. Given that Sensus Healthcare, Inc. has higher upside potential than Savara, Inc., analysts believe Sensus Healthcare, Inc. is more attractive than Savara, Inc..

Savara, Inc. has a beta of 0.226, which suggesting that the stock is 77.376% less volatile than S&P 500. In comparison Sensus Healthcare, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.559%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensus Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Sensus Healthcare, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than Sensus Healthcare, Inc. quarterly revenues of $6.9M. Savara, Inc.'s net income of -$29.6M is lower than Sensus Healthcare, Inc.'s net income of -$943K. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Sensus Healthcare, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 1.79x for Sensus Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.